Cardiovascular parameters
| Placebo | Irbesartan | p-value# | |||
| Baseline | 4 months | Baseline | 4 months | ||
| Systolic blood pressure mmHg | 129.8±14.6 | 129.1±15.5 | 131.0±14.7 | 124.4±16.1* | 0.26 |
| Diastolic blood pressure mmHg | 79.±7.8 | 77.6±8.0 | 78.7±9.2 | 75.5±9.1 | 0.45 |
| Cardiac frequency beats·min−1 | 88.8±13.1 | 87.3±21.4 | 82.5±10.6 | 83.2±17.0 | 0.68 |
| LVEDD mm | 43.1±9.0 | 46.5±7.7 | 44.3±7.5 | 45.4±6.9 | 0.4 |
| LVESD mm | 28.6±8.0 | 26.8±6.7 | 30.1±7.1 | 29.1±8.5 | 0.79 |
| RVEDD mm | 36.7±5.9 | 33.6±4.7 | 33.3±5.4 | 33.1±5.6 | 0.05 |
| Maximal cardiac frequency beats·min−1 | 124±15 | 120±19 | 128±15 | 125±16 | 0.62 |
| Maximal V'E L·min−1 | 28.3±8.9 | 28.6±14.1 | 29.2±12.2 | 29.3±12.1 | 0.89 |
| V'E/V'CO2 slope | 25.6±10.4 | 23.4±16.1 | 25.1±11.7 | 24.1±14.3 | 0.81 |
| Maximal respiratory quotient | 1.00±0.08 | 1.00±0.07 | 1.05±0.12 | 0.96±0.15 | 0.09 |
| Maximal V'O2 mL·min−1 | 957±286 | 885±433 | 989±442 | 986±411 | 0.41 |
Data are presented as mean±sd. LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; RVEDD: right ventricular end-diastolic diameter; V'E: minute ventilation; V'CO2: carbon dioxide production; V'O2: oxygen uptake. #: ANOVA for time by treatment interaction. *: p<0.05 (ANOVA for time). 1 mmHg = 0.133 kPa.